Cayenne Pepper Cataplasm - Safety Study

Low Back Pain Clinical Trial

— Munari04  

Official title:

Cayenne Pepper Cataplasm Application and Potential Side Effects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03440125
• Other study ID #: UP-MunariStudy
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: February 6, 2018
• Last updated: February 19, 2018
• Start date: March 15, 2016
• Est. completion date: December 15, 2016

Study information

• Verified date: February 2018
• Source: University of Primorska
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The beneficial analgesic effects of Rubefacenciae (redden skin substances), is known since 1830 as a treatment for pain, cramps, and disorders of the musculoskeletal system. Herbal cataplasms containing rubefacient substances, such as Cayenne pepper, are commonly used as natural medications to treat painful or aching areas in the case of acute or chronic back pain, and rheumatisms. In Vienna and lower Austria, a Cayenne Pepper Cataplasm (CPC) application containing Cayenne pepper and Kaolin powder in mixed proportion, is commonly used to treat musculoskeletal conditions of pain especially of the low back. However, a concern about the safety of such applications was recently raised.

Therefore, the aims of the present study are to evaluate the effects of 10x 20min CP cataplasm application as a single treatment or in combination with electrical stimulation and massage on selected functional and molecular parameters on i) healthy subjects and ii) subjects suffering from low back pain.

Description:

Musculoskeletal diseases, such as neck and low back pain, are widespread disorders in many developed countries. Their management is challenging, and it may have mounting socioeconomic burden. Several evidences in the literature demonstrate the efficacy of many therapeutic strategies in the treatment of these conditions, based on pharmacological or surgical interventions. Physical medicine therapies are good alternatives that may have beneficial effects, especially when used as first line of intervention before approaching more expensive pharmacological or invasive medications. The beneficial analgesic effects of Applicatio Epispasticorum of Rubefacenciae (redden skin substances), is known since 1830 as a treatment for pain, cramps, and disorders of the musculoskeletal system. Herbal cataplasms containing rubefacient substances, such as Cayenne pepper (CP), are commonly used as natural medications to treat painful or aching areas in the case of acute or chronic back pain, and rheumatisms. They are also used in pain involving joints caused by osteoarthritis. A galenic preparation composed of rubefacient substances of vegetable origin, which generated vasodilation and increase in blood circulation on the treated areas, was first prescribed in 1909 by Dr. Giuseppe Munari to treat pain of various areas of the locomotive system. He proposed a method based on applications prepared according to his own galenic formula that have become famous all over Italy and Europe. In Vienna and lower Austria, a Munari-like application containing CP and Kaolin powder in mixed proportion, is commonly used to treat musculoskeletal conditions of pain especially of the low back. The research on responses to CPC applications, particularly in combination with other modalities is scarce.

Therefore, the aims of the present study are firstly to evaluate the effects of 10x 20min CP cataplasm application on selected functional and molecular parameters on healthy subjects. Then, the same applications will be used on subjects suffering from low back pain (LBP) - both as a single treatment and in combination with electrical stimulation and massage.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 15, 2016
• Est. primary completion date: November 15, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Chronic low back pain (>3 months)

• Body mass index below 35 kg/m?2

Exclusion Criteria:

• pregnancy

• sensibility disorders (e.g. due to neurological disease)

• injuries, open wounds or rash in intervention area

• known hypersensitivity against the applied substances

• HIV, Hepatitis C and other due blood communicable infectious diseases

Related Conditions & MeSH terms

• Back Pain
• Low Back Pain

Intervention

Drug:
• Cayenne Pepper topical
20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water

Device:
• Electrical stimulation
Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)

Procedure:
• Massage
10 minutes of classical massage of low back pain area.

Locations

Country	Name	City	State
Slovakia	Facultiy of Physical Education and Sports, Comenius University of Bratislava	Bratislava
Slovenia	Faculty of Health Sciences	Izola

Sponsors (5)

Lead Sponsor	Collaborator
University of Primorska	Comenius University, Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation, S2P, Ltd., Wilhelminenspital Vienna

Countries where clinical trial is conducted

Slovakia,  Slovenia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in concentration of circulating biomarkers of inflammation, neudroendocrine stress and blood vessel activation	The blood analysis will include standard analysis of hemogram, C-reactive proteins, creatine-kinase, sedimentation, albumin and cortisol. Enzyme-linked immunosorbent assay (ELISA) will include Tumor necrosis factor-Alpha, Interleukin-6, Leukotriene B4 and P-Selectine. Additionally, microRNA analysis will be performed (gene numbers: 1, 21, 23, 25, 103, 126, 133, 146, 155, 199a, 199b, 191, 206, 451.	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Primary	Change in systolic and diastolic blood pressure	Systolic and diastolic blood pressure [mmHg], measured at both sides of the body with blood pressure gauge	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Primary	Heart rate	Heart rate (bpm), measured with heart rate monitor belt.	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Secondary	36-Item Short Form Survey (SF-36)	The Short Form (36) Health Survey (SF-36) is a patient-reported survey of patient health. It consists of eight scaled scores, which are the weighted sums all questions in their respective section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the higher is the disability.	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Secondary	Change in pain perception	Pain perception during rest and movement assessed with visual analogue scale (0-10). 0 represents no pain, and 10 represents severe pain.	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Secondary	EQ-5D- 5L questionnaire	EQ-5D- 5L questionnaire includes following aspects: mobility, care, usual activities, pain/discomfort, anxiety/depression, crosswalk-index, self-feeling of health. Each aspect is evaluated on a 1-5 scale, with following descriptions of levels: having no problems, having slight problems, having moderate problems, having severe problems and being unable to do/having extreme problems. Visual analogue scale is the second part of the questionnaire, asking to mark health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. There are notes at the both ends of the scale that the bottom rate (0) corresponds to " the worst health you can imagine", and the highest rate (100) corresponds to "the best health you can imagine".	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Secondary	Oswestry disability index (ODI)	ODI will be used only in LBP arms (Arm 2 and 3). ODI is commonly used by clinicians and researchers to quantify disability for low back pain.	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Secondary	Skin Sensory Function	Skin sensory function will be assessed by 2-point discrimination test (which is carried out using two pins, oriented in medial-lateral direction and pressed perpendicularly to the skin, with the medial pin being 3 cm laterally from the L3 spinal process. The subject is asked to report whether he/she felt one or two pins) and mono filament/light touch sensitivity tests (monofilaments calibrated to 0.025, 0.07, 2, 5, and 10 grams The subject is asked to report when he/she felt touching the skin with a monofilament 3 cm laterally from L3 spinal process). The lightest mono filament and the lowest pin inter-distance are take as final outcome measures.	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Secondary	Flexibility	Assessment of total spine flexibility (forward bend test) and separately for the lumbar part (Schober's test) and thoracic part.	Before the application, 45 minutes after 10th application and 48 hours after 10th application
Secondary	Skin Temperature	Skin temperature [°C] at the site of application (low back) and at the control part of the body (neck), measured with a laser thermometer.	Before the application, 45 minutes after 10th application and 48 hours after 10th application